The Nifty Smallcap 500 index reached a 52-week high of 21,174.60, gaining 0.42% during Monday's intra-day trading session on the National Stock Exchange. According to reports from Business Standard, the index demonstrated strong momentum with 152 stocks from the index gaining more than 2% in an otherwise weak market environment. The performance contrasted sharply with the Nifty 50, which declined 0.52% during the same period. In the past three months, the Smallcap 500 has significantly outperformed the broader market, surging 11% compared to a 3.4% rise in the BSE Sensex. At 02:11 PM, the Nifty Smallcap 500 index was up 0.10% compared to the Nifty 50's decline, highlighting the continued strength in small-cap momentum.
Several stocks from the Nifty Smallcap 500 index delivered exceptional gains, with PC Jeweller, Strides Pharma Science, Syrma, ION Exchange India and Avalon Technologies soaring between 10-18% during intra-day trading. As reported by Business Standard, the performance was broad-based with 36 stocks gaining between 5-9%, 38 stocks rising 4% each, 35 adding 3% each and 38 stocks up 2% each in Monday's session. The rally was particularly notable as it occurred in an otherwise weak market environment, highlighting the strength of small-cap momentum and the continued outperformance of select segments.
Syrma Technologies emerged as the standout performer, hitting a new high of ₹1,626.50 with a remarkable 12% surge. According to Business Standard, the rally was accompanied by heavy trading volume with a combined 10.95 million equity shares representing 6% of the company's total equity changing hands on both NSE and BSE exchanges. The strong performance reflects growing investor confidence in the electronics components sector, particularly as India continues its indigenization efforts through schemes like the Mobile Production Linked Incentive (PLI) 1 (FY21-26), which successfully assembled 99% of phones domestically. However, Jefferies recommends prudence in Syrma with a Hold rating at 57x after its +105% rally year-to-date, suggesting caution despite the positive momentum.
Strides Pharma Science soared 12% to ₹1,185 during intra-day trading, with 2.2 million equity shares changing hands across exchanges. As reported by Business Standard, the pharmaceutical company has been deliberate in diversifying its business across geographies, with Ex-U.S. markets growing steadily and increasing their contribution to approximately 46% of revenue in FY26 and nearing 50% on a quarterly exit basis. The company specializes in niche and technically complex generic finished dosage formulations, with a portfolio strategy focused on driving value-led growth through addressing unmet market needs and enhancing product differentiation. Strides said in its FY26 annual report that its portfolio strategy is increasingly focused on driving value-led growth by addressing unmet market needs, strengthening brand equity and enhancing product differentiation, enabling improved pricing power while building a more resilient and sustainable business.
According to Vinod Nair, Head of Research at Geojit Investments, stock- and sector-specific buying remained evident across the broader market, with small-cap indices touching fresh intraday lifetime highs. As reported by Business Standard, strong earnings momentum, resilient economic growth, and robust domestic demand continue to underpin investor confidence in the broader market. The Nifty-50 has largely remained flat over the past year due to persistent geopolitical headwinds and sustained foreign institutional investor selling, particularly in index heavyweights. However, select pockets of the small and midcap segment have continued to deliver strong earnings growth, driving the Midcap and Smallcap indices to new all-time highs. Motilal Oswal Financial Services noted that with strengthening earnings growth and improving breadth of growth, the risk-reward profile is becoming increasingly favorable, enhancing India's attractiveness from an FII perspective.
